Company news
Hemostemix Inc (TSXV:HEM) news
Hemostemix Inc news releases on 6ix. Latest, Sep 28, 2026: Hemostemix to Attend Centurion One Capital's 4th Annual Bahamas Summit
Press releases & updates
Hemostemix to Attend Centurion One Capital's 4th Annual Bahamas Summit
September 28, 2026
Hemostemix Non Brokered Private Placement
September 23, 2026
Hemostemix Commercializes Its Vascular Dementia Clinical Trial of VesCell(TM) Under LARTA
August 20, 2026
Dr. Ernst von Schwarz, Principal Investigator of Hemostemix VesCell(TM) Longevity Clinical Trial
August 12, 2026
Hemostemix Closes Second Tranche of Private Placement and Obtains Extension to August 14, 2026
July 30, 2026
Hemostemix' Longevity Phase I Clinical Trial Leveraging VesCell(TM)'s Excellent Results
July 28, 2026
Hemostemix : grants 6,280,000 options
July 22, 2026
Commercialization Application Filed by Hemostemix for the Treatment of Vascular Dementia, Angina and Pain
July 8, 2026
Hemostemix Closes $360,000 First Tranche of Private Placement
June 26, 2026
Hemostemix' $1,000,000 Private Placement and Update
June 17, 2026
Dr. Desiree Cox Appointed to Hemostemix Board of Directors
May 26, 2026
Hemostemix : Dr. Desirée Cox Appointed to Hemostemix’ Board of Directors
May 25, 2026
Hemostemix : $1,000,000 Private Placement
May 21, 2026
HEMOSTEMIX : CLOSES $303,967 PRIVATE PLACEMENT AT $0.12 PER SHARE
March 19, 2026
Hemostemix Leadership Attending Abundance360 Summit
March 9, 2026
Hemostemix Appoints Renowned Vascular Surgeon and Principal Investigator, Dr. York Hsiang, as Business Consultant to Advance First Nations-Led Healthcare Partnerships
February 3, 2026
Hemostemix Receives FDA Support for Its Basket Protocol Approach
January 16, 2026
Hemostemix Closes $480,000 Private Placement at $0.12 per Share
December 31, 2025
Hemostemix Appoints Dr. David B. Alper, to Lead Multidisciplinary Physician Education in the Use of ACP-01
December 23, 2025
Hemostemix : Granted Trademark 'KNOW YOUR HEALTH' in Japan.
December 18, 2025
Hemostemix : to Showcase Breakthrough Wound Healing Therapy at Innovations in Wound Care Conference Florida
December 18, 2025
Hemostemix : Dr. William R. Shankle to Advance ACP-01 as a Treatment for Vascular Dementia
December 18, 2025
Hemostemix CEO Introduces Conformal Consciousness Hypothesis A = E/(hv)
December 11, 2025
Hemostemix Grants Stock Options
December 11, 2025
Hemostemix Inc. Announces FDA Pre-IND Meeting and NBPP of $960,000
December 10, 2025
Hemostemix Welcomes Shaune Harding, OStJ, RN as Director of Patient Care & Clinical Operations
December 4, 2025
Hemostemix Featured at Innovations in Wound Healing 2025, Key West, December 11-14
December 3, 2025
Hemostemix to Attend DFCon San Antonio and Closed its Private Placement
December 2, 2025
Hemostemix Starts its Roll-up of Cardiology Practices, Acquiring its First Two
November 26, 2025
Dr. William R. Shankle to Advance ACP-01 as a Treatment for Vascular Dementia
November 20, 2025
Hemostemix Closes CDN$280,594 Private Placement
November 18, 2025
Hemostemix to Showcase Breakthrough Wound Healing Therapy at Innovations in Wound Care Conference Florida
November 18, 2025
Hemostemix Presents ACP-01 Data at University of Florida Grand Rounds: Highlights Strong Safety, Functional Gains, and Florida Access Pathway
November 13, 2025
Hemostemix Closes Private Placement of $461,230
November 4, 2025
Hemostemix's Boots on the Ground in Florida October Update
October 30, 2025
Hemostemix Announces Its Webinar for Florida Vascular Surgeons: Autologous Stem Cell Therapy for CLTI
October 28, 2025
Hemostemix Granted Trademark "KNOW YOUR HEALTH" in Japan, International Registration No. 1744775 Covers Stem Cell Preparations and Research in Classes 1, 5, 42
October 22, 2025
Hemostemix Adds the Treatment of Refractory Angina to Its Phase 1 Basket Protocol
October 15, 2025
Hemostemix Files for Ethics Approval of its Study of Vascular Dementia
October 9, 2025
Hemostemix's Insider Lead Order of $330,000 Private Placement
October 7, 2025
Hemostemix Files FDA Submission for Basket Protocol (Filing 1517) to Advance ACP-01 (VesCell(TM)) Across Multiple Ischemic and Vascular Indications Simultaneously
September 23, 2025
Life Sciences Virtual Investor Forum: Presentations Now Available for Online Viewing
September 18, 2025
Hemostemix to Present at Life Science Investor Forum
September 17, 2025
Hemostemix to Present Its Clinical Data of the Treatment of Severe Angina
September 16, 2025
Life Science Virtual Investor Forum Agenda Announced for September 18th
September 16, 2025
Hemostemix Announces TSXV Approval of Debt Settlement at $0.20 per Share
September 10, 2025
Hemostemix Announces Private Placement
September 9, 2025
Hemostemix Launches Enhanced HubSpot-Powered Websites to Support Global Marketing & Sales of ACP-01 for No-Option Patients
September 9, 2025
Hemostemix's VesCell.Health Launched in Florida
September 4, 2025
Howie's 17+ Years After VesCell(TM): Following Hemostemix's Heart Patients
September 3, 2025